There must be a story (and possibly a song) here!

AstraZeneca said Thursday that Dave Mott, president and chief executive of MedImmune, its biologics business unit, has decided to leave the company at the end of July.

Tony Zook, chief executive of AstraZeneca's North American business, has been appointed as head of MedImmune on an interim basis until a permanent successor is identified, the company said.

James Young, MedImmune's president of research and development, resigned earlier this month..........!